G ain-of-function variants in the PCSK9 gene (proprotein convertase subtilisin/kexin type 9) lead to high levels of low-density lipoprotein cholesterol (LDL-C), whereas loss-offunction (LOF) variants are associated with lower LDL-C levels. [1] [2] [3] [4] Although gain-of-function mutations are rare and occur in <0.1% of the general population, LOF variants in PCSK9 are present in 1% to 3% of adults.
PCSK9 LOF Variants and Cardiovascular Outcomes

Methods
Data Sources
Analyses were performed by combining data from 8 populationbased cohort studies and 1 randomized controlled trial of statin therapy. Descriptions, methods, and acknowledgments for each study are included in the Data Supplement. Eight of the 9 studies are in the CHARGE Consortium (Cohorts for Heart and Aging Research in Genomic Epidemiology) . The primary goal of the CHARGE Consortium is to provide high-quality, reliable, and valid estimates of associations between genotypes with cardiovascular and aging phenotypes across multiple studies. 7 Studies participating in CHARGE were conducted in the United States and Europe and include genome-wide data. Each study has its own administrative structure and set of investigators. For the current analyses, we included 7 observational cohorts from CHARGE: the AGES (Age, Gene, Environment, Susceptibility StudyReykjavik), ARIC Study (Atherosclerosis Risk in Communities), CHS (Cardiovascular Health Study), FHS (Framingham Heart Study), Health ABC (Health, Aging, and Body Composition) Study, JHS (Jackson Heart Study), and MESA (Multi-Ethnic Study of Atherosclerosis). We also included a statin trial participating in CHARGE, the PROSPER Study (PROspective Study of Pravastatin in the Elderly at Risk for vascular disease). In addition to data from these 8 participating CHARGE studies, meta-analyses included data from the observational REGARDS Study (REasons for Geographic And Racial Differences in Stroke). 8 PCSK9 LOF variants Y142X (rs67608943) and C679X (rs28362286) were genotyped for 17 459 blacks in 6 studies (ARIC, CHS, Health ABC, JHS, MESA, and REGARDS). PCSK9 LOF variant R46L (rs11591147) was genotyped for 31 306 whites in 8 studies (AGES, ARIC, CHS, FHS, Health ABC, MESA, PROSPER, and REGARDS). FHS, PROSPER, and AGES consisted only of white participants, and JHS consisted only of black participants. For the purposes of this analysis, participants were considered to have a PCSK9 LOF variant if they carried at least 1 minor allele at Y142X or C679X (in blacks) or at least 1 minor allele at R46L (in whites); this nomenclature indicates the amino acid change not the nucleotide change.
To provide a larger number of participants taking statins while maximizing follow-up time and the number of outcomes that occurred, studies selected their participants' first available visit date after January 1, 1995, for the assessment of LDL-C levels and as the baseline to initiate follow-up for CHD and stroke outcomes. The Institutional Review Boards of participating institutions for all 9 studies approved this research. All participants gave written informed consent, including for genetic research.
Statistical Analyses
All analyses were performed separately for blacks and whites. For each study, mean age, the percentage of participants who were male, and the prevalence of diabetes mellitus, history of CHD, history of stroke, current smoking, and statin use were calculated by PCSK9 LOF variant status. Linear regression models were used to calculate average differences in fasting LDL-C levels by PCSK9 LOF variant status, after adjustment for age, sex, study center (for multicenter studies), region of residence (for REGARDS), and statin use. Regression model results from each study were pooled using fixedeffect inverse variance-weighted models. Cochran's Q was calculated to assess homogeneity of estimates.
Incident CHD and stroke (any subtype) during follow-up were studied after excluding participants with a history of each respective condition at their baseline study visit. In some studies, no CHD or stroke events occurred among participants with PCSK9 LOF variants. To avoid bias created when omitting these studies, unadjusted pooled Mantel-Haenszel odds ratios (ORs) for CHD and stroke were calculated using inverse-treatment arm weighted continuity correction factors. 9 The Breslow-Day test was calculated to assess homogeneity of estimates.
In secondary analyses, we calculated participant characteristics and examined the associations between PCSK9 LOF variants and LDL-C and incident CHD and stroke stratified by statin use at baseline. We also conducted separate sensitivity analyses examining whether results from individual studies differed by analysis method. For these analyses, Cox regression models were performed to estimate the hazard ratios (HRs) for associations between the presence of a PCSK9 LOF variant and incident CHD and stroke, adjusted for age, sex, study center (for multicenter studies), region (for REGARDS), and statin use. HRs could not be calculated for studies where no CHD or stroke events occurred among participants with PCSK9 LOF variants. Therefore, these studies were not included in this sensitivity analysis. We performed an additional sensitivity analysis in the REGARDS Study cohort calculating the OR for the association of PCSK9 LOF variants and ischemic stroke events, while censoring follow-up when hemorrhagic stroke events occurred. Meta-analyses were performed in SAS 9.3 (Cary, NC) and STATA 13.1 (College Station, TX). P values <0.05 were considered statistically significant.
Results
Participant Characteristics
Among 17 459 blacks, 403 (2.3%) had a Y142X or C679X PCSK9 LOF variant, and among 31 306 whites, 955 (3.1%) had an R46L PCSK9 LOF variant. The mean age ranged from 47.9 years among white participants in FHS without PCSK9 LOF variants to 79.0 years among white participants in CHS with PCSK9 LOF variants (Table) . Differences in characteristics across PCSK9 status were larger in studies with smaller numbers of participants. In all studies except PROSPER (a randomized trial), participants with PCSK9 LOF variants were less likely to be taking statins than those without PCSK9 LOF variants.
PCSK9 LOF Variants, LDL-C, CHD, and Stroke
Among blacks, PCSK9 LOF variants were associated with lower LDL-C levels in each study (Figure 1) . In a pooled analysis of 6 studies with blacks, which included adjustment for age, sex, and statin use, PCSK9 LOF variants were associated with 35 mg/dL (95% confidence intervals [CI], 32-39) lower LDL-C levels. Among whites, having the PCSK9 LOF variant was associated with lower LDL-C levels in each study except REGARDS. In pooled analyses among whites in 8 studies and adjusted for age, sex, and statin use, the PCSK9 LOF variant was associated with 13 mg/dL (95% CI, 11-16) lower LDL-C levels.
No CHD events occurred among black participants with PCSK9 LOF variants in CHS or JHS (Figure 2 ). In pooled analyses of 6 studies with blacks, PCSK9 LOF variants were associated with an OR for CHD of 0.51 (95% CI, 0.28-0.92). Among whites, the PCSK9 LOF variant was associated with a statistically significant lower CHD risk in only REGARDS (OR, 0.20; 95% CI, 0.05-0.85). Pooling white participants in 8 studies, the OR for CHD associated with having the PCSK9 LOF variant was 0.82 (95% CI, 0.63-1.06).
Among blacks, no stroke events occurred among participants with PCSK9 LOF variants in CHS, JHS, or MESA ( Figure 3) . In pooled analyses of 6 studies with blacks, PCSK9 LOF variants were associated with an OR for stroke of 0.84 (95% CI, 0.48-1.47). Pooling 8 studies with white participants, the PCSK9 LOF variant was associated with an OR for stroke of 1.06 (95% CI, 0.80-1.41). 
Results Stratified by Statin Use
Characteristics of participants not taking and taking statins are provided by PCSK9 LOF variant status in Tables I and II in the Data Supplement. The associations of PCSK9 LOF variants with LDL-C, CHD, and stroke among participants not taking statins were similar to associations in the overall population (Table III in the Data Supplement). In pooled analyses of participants taking statins, PCSK9 LOF variants were associated lower LDL-C levels in blacks but were not associated with LDL-C levels in whites (Table IV in 
Sensitivity Analyses
When using Cox regression models to calculate HRs, the associations of PCSK9 LOF variants and incident CHD and stroke were similar to the primary analyses (Tables V through VII in the Data Supplement). In the REGARDS Study, the OR for ischemic stroke was 1.42 (95% CI, 0.67-3.03) for blacks and 1.67 (95% CI, 0.79-3.52) for whites.
Discussion
In this meta-analysis of 17 459 blacks and 31 306 whites, PCSK9 LOF genetic variants were associated with lower LDL-C. For whites in REGARDS, the total number of participants is unweighted, but the remaining characteristics are weighted to represent their proportions in the full white cohort.
Age is presented as mean (standard deviation), except for among whites in REGARDS which displays mean (standard error) because characteristics are weighted. Remaining characteristics are presented as percentages. The PCSK9 gene encodes a protease that binds to the low-density lipoprotein receptor and leads to its degradation. PCSK9 gain-of-function variants result in decreased low-density lipoprotein receptor activity, leading to a rare form of autosomal dominant familial hypercholesterolemia. 10 Conversely, the more common PCSK9 LOF variants result in preserved low-density lipoprotein receptor activity and lower circulating LDL-C levels.
2,10 The current analyses confirm previous observational studies that found PCSK9 LOF variants to be associated with lower LDL-C levels. Y142X and C679X nonsense variants are more common in blacks and have been consistently associated with ≥30 mg/dL lower LDL-C levels. 2, 3, 11 The current analyses found similar reductions in LDL-C levels attributable to the Y142X and C679X variants as previously reported. The R46L missense variant is more common in whites and has been associated with ≥15 mg/ dL lower LDL-C levels in previous reports. [2] [3] [4] [12] [13] [14] The pooled estimates from the current analyses found that the R46L variant was associated with 13 mg/dL lower LDL-C. 
LOF Variants and Cardiovascular Outcomes
Previous studies have found PCSK9 LOF variants to be associated with a lower risk for CHD in blacks and whites. 2, 4 In a previous meta-analysis of 55 359 individuals in the United States and Europe, the R46L variant was associated with an OR of 0.72 (95% CI, 0.62-0.84) for ischemic heart disease. 4 In a previous report from the ARIC Study, the R46L variant was associated with a HR for CHD of 0.11 (95% CI, 0.02-0.81) in 3363 black participants and 0.50 (95% CI, 0.32-0.79) in 9524 white participants. 2 A multinational study of whites comparing 1454 early-onset myocardial infarction cases to 1617 myocardial infarction-free controls found the R46L gene to be associated with an OR for myocardial infarction of 0.40 (95% CI, 0.26-0.61). 15 Differences in these estimates from the current analyses may have occurred because most previous studies did not exclude participants with prevalent heart disease. Additionally, the current analyses used post-1995 study visits as the baseline to have larger numbers of participants taking statins for secondary analyses. A recent analysis of REGARDS, ARIC, and Kaiser Permanente Southern California data found that the preferential use of statins by high-risk individuals (eg, patients with diabetes mellitus) in more contemporary cohorts may lead to bias that attenuates the association between lipids and CHD. 16 In the current meta-analyses, a protective association between PCSK9 LOF variants and incident CHD events was present, which was statistically significant among blacks. These results provide evidence that the larger differences in lifetime LDL-C levels associated with the Y142X and C679X variants in blacks, compared with R46L variants in whites, are associated with larger differences in CHD risk. Previous meta-analyses of ezetimibe and other nonstatin LDL-C-lowering medication trials have also found greater LDL-C lowering to be associated with larger CHD risk reduction. 17, 18 The association between PCSK9 LOF variants and stroke has not been extensively studied. 2 A previous analysis of the ARIC Study, which included 6 strokes among blacks with a Y142X or C679X variant in and 9 strokes among whites with a R46L variant, reported no difference in stroke rates by PCSK9 LOF variant status. 2 The current analyses, which included 13 strokes among blacks with a Y142X or C679X variant and 58 strokes among whites with a R46L variant, are consistent with the ARIC results and with previous observational studies, wherein LDL-C was not associated with stroke risk. 2, 19, 20 A recent pooled analyses of observational studies found that R46L and other PCSK9 LOF variants associated with smaller differences in LDL-C were not associated with stroke. 6 Among 6276 FHS participants, LDL-C was not associated with ischemic stroke risk (HR=1.08; 95% CI, 0.85-1.36 per SD increase in log-transformed LDL-C). 19 This result in FHS confirmed previous reports that lower LDL-C was not associated with reduced ischemic stroke risk. 21, 22 However, strokes have varying causes and LDL-C has different associations with different stroke subtypes. 21 It has been noted that hypertension and diabetes mellitus are the dominant risk factors for strokes originating from lipohyalinosis but that serum lipids may contribute to strokes associated with carotid atherosclerosis. 21 Additionally, a meta-analysis of 23 studies with 1 430 141 participants found that low LDL-C levels were associated with increased hemorrhagic stroke risk. 23 It is not clear whether this association is causal or reflects high hemorrhagic stroke risk in individuals with general poor health status. 24 In the current study, no association was present between PCSK9 LOF variants and strokes of all subtypes or ischemic strokes. We could not examine associations between PCSK9 LOF variants and hemorrhagic stroke because this outcome is too rare.
Clinical trials of lipid-lowering medications have also given inconsistent results on whether lower LDL-C levels lead to lower stroke risk. A 2013 Cochrane Collaboration metaanalysis of randomized trials indicated that statin treatment reduces stroke risk (relative risk = 0.78; 95% CI, 0.68-0.89), and a 2015 meta-analysis of 27 statin trials including 174 000 participants found that more intensive statin treatment further reduces stroke risk. 25, 26 It has been hypothesized that the lower stroke risk may not be directly related to the LDL-C-lowering effects of statins but rather from pleiotropic effects such as the lowering of triglyceride levels and reduction of inflammation. 20, 27, 28 However, a 2015 meta-analysis of 7 trials containing 31 048 patients found that ezetimibe, which is prescribed primarily because of its role in lowering LDL-C levels, was associated with a relative risk of 0.84 (95% CI, 0.74-0.95) for stroke. 18 Randomized trials of pharmacological PCSK9 inhibitors, in which stroke is evaluated as a secondary end point, will provide more clarity on this association. 29, 30 In the current analyses of blacks taking statins, PCSK9 LOF variants were associated with an increased risk for stroke. However, the sample for the stroke analyses in blacks taking statins had only 30 participants with PCSK9 LOF variants, 3 of whom had stroke events. Therefore, it is possible that the higher stroke risk for participants with PCSK9 LOF variants was because of chance. In addition, 28 of the 30 participants with PCSK9 LOF variants, including all 3 stroke events, were from a single study (REGARDS). Confounding by indication may have affected analyses among REGARDS participants taking statins. Specifically, individuals with PCSK9 LOF variants have lower LDL-C levels and those who are prescribed statins are more likely to have a higher prevalence of cardiovascular disease risk factors. 16 Among black participants in the REGARDS Study taking statins, those with a PCSK9 LOF variant, compared to those without a PCSK9 LOF variant, had higher prevalence of a history of CHD, diabetes, and smoking Because of the small number of blacks taking statins in REGARDS who had a stroke, we could not further explore possible confounding. However, there was no association between the presence of a PCSK9 LOF variant and stroke among whites taking statins. In the current analysis, 90 (66%) of the 136 white participants taking statins with a PCSK9 LOF variant were in PROSPER, a randomized statin trial. Among whites in PROSPER, participants with and without a PCSK9 LOF variant had similar prevalence of a history of CHD, diabetes mellitus, and smoking.
The current analyses have many strengths including the availability of data on PCSK9 LOF variants, LDL-C, and cardiovascular outcomes from 9 studies. The populations included a large number of blacks and whites from the United States and Europe. Additionally, the contemporary data examined in this study facilitated analyses stratified by statin use. Results should be considered in the context of known and potential limitations. Methods varied between studies, including event retrieval methods and event definitions. Another potential PCSK9 LOF Variants and Cardiovascular Outcomes limitation of these analyses is the introduction of survivor bias through the exclusion of individuals with previous CHD and stroke events. However, the prevalence of previous CHD and stroke at baseline was not consistently higher among participants with PCSK9 LOF variants across cohorts. Because no events occurred among participants with PCSK9 LOF variants in some studies, the associations of PCSK9 LOF variants and CHD and stroke in primary analyses were calculated unadjusted. However, in sensitivity analyses, unadjusted ORs and adjusted HRs were similar in the studies in which both could be calculated. Although we combined data from 9 studies, the numbers of CHD and stroke events were low among participants with PCSK9 LOF variants, particularly in models stratified by statin use, and limited the ability to adjust for confounders. The low number of events resulted in high variability in the estimates for an association between each of the individual studies. Larger studies are needed determine the replicability of the pooled estimates of this analysis. 31 Also, statin use was defined at a single time point, and race was self-reported without incorporating any measures of genetic admixture.
In conclusion, this meta-analysis consisting of 17 459 blacks and 31 306 white participants from 9 studies in the United States and Europe confirmed that PCSK9 LOF variants are associated with lower LDL-C among blacks and whites. PCSK9 Y142X or C679X variants genotyped in blacks, compared with the PCSK9 R46L variant genotyped in whites, were associated with larger reductions in LDL-C and CHD incidence. PCSK9 LOF variants were not associated with stroke risk. These results suggest that lifetime lower LDL-C levels are associated with lower CHD risk and support a doseresponse association between LDL-C and CHD, corroborating the results from meta-analyses of ezetimibe and other LDL-C-lowering medication trials. 17, 18 The current report supports recent analyses of clinical trials that found a 50% reduction in the risk for cardiovascular events in participants randomized to LDL-lowering monoclonal antibody PCSK9 inhibitors, compared with their counterparts randomized to placebo. 10, 29, 30, 32 The results of the current analyses were less clear on stroke. Future studies of PCSK9 inhibitors and other lipid-lowering medications should be designed and adequately powered to examine the association between LDL-C and stroke, separate from other cardiovascular events.
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